Integrated Early Drug Development Services — Altasciences

For us, integrated early drug development services is most valuable when every activity is tied to a clear program question. We begin by understanding the development stage, available inputs, known risks, and the audience for the final deliverables. From there, we define a scope that is scientifically grounded, operationally realistic, and designed to produce information your team can act on.

Our integrated early drug development services capabilities

We are an integrated early-phase CRO/CDMO offering preclinical safety testing, clinical pharmacology, bioanalysis, research support, and manufacturing and analytical services. This page focuses on integrated early drug development services. This service is best suited to sponsors looking for scientific and operational continuity across a defined development milestone. The program should be designed around the molecule, development stage, safety and exposure questions, clinical milestone, sample plan, and required regulatory deliverables. Next conversation: We can confirm current scope, availability, required inputs, deliverables, and our team that would lead the work. This work sits within our Clinical Trials, Pre-Clinical Research capabilities and is coordinated with the wider program context when the scope requires it.

• A scope for integrated early drug development services tied to the program objective
• Defined inputs, responsibilities, review points, and decision criteria
• Deliverables organized for scientific and operational follow-through

How we shape the scope

During scoping, we work through the objective, acceptance criteria, dependencies, and potential decision points in plain language. We also identify assumptions that need to be tested before they become schedule or budget problems. The resulting plan defines responsibilities on both sides, shows where reviews will occur, and makes clear how changes in inputs or findings will be handled. This creates a shared operating picture without locking the project into details that should remain flexible.

Working with Altasciences

Throughout the engagement, we keep communication close to the work. Updates focus on progress, emerging observations, open decisions, and anything that could affect scope or timing. We do not wait for a final report to raise an issue that may change the path. When your internal scientists, clinicians, quality teams, or program leaders need different levels of detail, we organize discussions so each group can evaluate the information relevant to its role.

Deliverables built for the next decision

A deliverable is only useful if its structure matches the decision it supports. We therefore align early on content, format, traceability, and the expected level of interpretation. The completed package reflects the activities actually performed and separates results from recommendations where that distinction matters. We walk the team through key findings and open items, making it easier to carry the work into the next experiment, study activity, development stage, or internal governance review.

Before execution, we also confirm how the work will connect with adjacent activities and which handoffs could affect quality, timing, or interpretation. That check helps us identify missing inputs early, avoid duplicated effort, and keep the completed package consistent with the program's immediate priorities. We record the decisions made during this alignment so the project team has a stable reference as work progresses.

Planning your integrated early drug development services project with Altasciences

To plan a integrated early drug development services project, share the program stage, primary objective, available inputs, known constraints, desired timing, and the decision the work needs to support. We will use that information to frame a focused technical discussion and return a scope that identifies the proposed approach, responsibilities, assumptions, review points, deliverables, and major cost or schedule drivers.